Table 4.
Most Common Adverse Events by Treatment (using frequencies, considering the primary system affected)
| Placebo Control (from 76 subjects, nAE = 412) |
80 mg/day (from 82 subjects, nAE = 427) |
120 mg/day (from 76 subjects, nAE = 401) |
||||||
|---|---|---|---|---|---|---|---|---|
| No. | %a | No. | %a | No. | %a | |||
| Upper Respiratory Infection | 98 | 24% | Upper Respiratory Infection | 95 | 22% | Upper Respiratory Infection | 86 | 21% |
| LDL Increase | 15 | 4% | Urinary Tract Infection | 23 | 5% | Pain | 11 | 3% |
| Sinusitis | 14 | 3% | Flu | 17 | 4% | LDL Increase | 10 | 2% |
| Gastroenteritis | 13 | 3% | Gastroenteritis | 15 | 4% | Flu | 9 | 2% |
| Urinary Tract Infection | 13 | 3% | Sinusitis | 12 | 3% | Sinusitis | 9 | 2% |
| Joint Trauma | 12 | 3% | Pain | 11 | 3% | Joint Trauma | 8 | 2% |
| Flu | 11 | 3% | LDL Increase | 10 | 2% | Urinary Tract Infection | 8 | 2% |
| Insomnia | 10 | 2% | Tooth Disorder | 8 | 2% | Gastroenteritis | 6 | 1% |
| Pain | 10 | 2% | Joint Trauma | 7 | 2% | Headache | 6 | 1% |
| Headache | 9 | 2% | Insomnia | 6 | 1% | Tooth Disorder | 6 | 1% |
| Tooth Disorder | 4 | 1% | Iron Decrease | 5 | 1% | Iron Decrease | 3 | 1% |
a
Percent of adverse events for a given adverse event is based on the number of adverse events in relation to the total number for each treatment.